The FDA has approved Purified Cortrophin Gel (repository corticotropin injection USP) in a prefilled syringe presentation.

Jefferies initiated coverage of ANI Pharmaceuticals (ANIP) with a Buy rating and $80 price target The firm expects continued momentum for the ...

The FDA approved a prefilled syringe format for Ani's purified Cortrophin Gel that should ease administration for MS patients ...

ANI Pharmaceuticals (ANIP) stock was granted an Overweight rating by J.P. Morgan on Wednesday based on the company's growth ...

JPMorgan initiated coverage of ANI Pharmaceuticals (ANIP) with an Overweight rating and $85 price target ANI is a specialty pharmaceuticals ...

Cortrophin Gel is a prescription medicine that is injected subcutaneously or intramuscularly indicated for severe acute and ...

PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval of Purified ...

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) ...

Q4 2024 Earnings Call Transcript February 28, 2025 ANI Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

ANI Pharmaceuticals Inc (ANIP) reports a robust Q4 2024 performance with significant revenue increases and optimistic 2025 projections, driven by strong rare disease and generics segments.

Rare Disease Revenue: $87 million in Q4 2024, more than doubled from the prior year. Cortrophin Gel Revenue: $59.4 million in Q4 2024, up 42% year-over-year. ILUVIEN and YUTIQ Revenue: $27.6 ...

Generated record quarterly net revenues of $190.6 million, representing year-over-year growth of 44.8% Total Rare Disease quarterly net revenue of $87.0 million, which includes: Record quarterly net ...